Insulet Yönetim

Yönetim kriter kontrolleri 3/4

Insulet CEO'su Jim Hollingshead, Jun2022 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 12.38M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.8% maaş ve 93.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.025% ine doğrudan sahiptir ve bu hisseler € 4.32M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.4 yıl ve 4 yıldır.

Anahtar bilgiler

Jim Hollingshead

İcra Kurulu Başkanı

US$12.4m

Toplam tazminat

CEO maaş yüzdesi	6.8%
CEO görev süresi	2.4yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	4yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jim Hollingshead'un ücretlendirmesi Insulet'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$421m
Jun 30 2024	n/a	n/a	US$395m
Mar 31 2024	n/a	n/a	US$234m
Dec 31 2023	US$12m	US$842k	US$206m
Sep 30 2023	n/a	n/a	US$120m
Jun 30 2023	n/a	n/a	US$63m
Mar 31 2023	n/a	n/a	US$600k
Dec 31 2022	US$11m	US$440k	US$5m
Sep 30 2022	n/a	n/a	US$17m
Jun 30 2022	n/a	n/a	US$35m
Mar 31 2022	n/a	n/a	US$45m
Dec 31 2021	US$290k	n/a	US$17m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	US$9m
Dec 31 2020	US$259k	n/a	US$7m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$18m
Mar 31 2020	n/a	n/a	US$5m
Dec 31 2019	US$261k	n/a	US$12m

Tazminat ve Piyasa: Jim 'nin toplam tazminatı ($USD 12.38M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.90M ).

Tazminat ve Kazançlar: Jim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jim Hollingshead (61 yo)

2.4yrs

Görev süresi

US$12,379,765

Tazminat

Dr. James R. Hollingshead, also known as Jim, Ph.D. had been President of Sleep & Respiratory Care Business at ResMed Inc. since July 2020 until May 05, 2022 and served as its President of Sleep Business s...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Hollingshead	President	2.4yrs	US$12.38m	0.025% € 4.3m
Lauren Budden	Group VP	5.6yrs	US$1.44m	0.0061% € 1.1m
Mark Field	Senior VP & CTO	1.3yrs	US$2.37m	0.014% € 2.4m
John Kapples	Senior VP & General Counsel	5.7yrs	US$2.47m	0.021% € 3.7m
Eric Benjamin	Executive VP	6.8yrs	US$3.14m	0.024% € 4.2m
Ana Chadwick	Executive VP	less than a year	Veri yok	0.00014% € 24.3k
Prem Singh	Senior Vice President of Global Operations	1.8yrs	Veri yok	0.0052% € 903.0k
Deborah Gordon	Vice President of Investor Relations	9.8yrs	Veri yok	Veri yok
Laetitia Cousin	Senior VP of Regulatory Affairs	1.9yrs	Veri yok	0.0044% € 767.8k
Angela Wiczek	Senior Director of Corporate Communications	no data	Veri yok	Veri yok
Philip Hildale	Senior Vice President of Sales & Customer Care	9.8yrs	Veri yok	Veri yok
Andrew Isaacson	Senior VP of Strategy & Corporate Development	less than a year	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: GOV 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Hollingshead	President	5.3yrs	US$12.38m	0.025% € 4.3m
Elizabeth Weatherman	Independent Director	2.8yrs	US$322.50k	0.0040% € 686.3k
Timothy Scannell	Independent Chairman	10.3yrs	US$387.10k	0.042% € 7.2m
Robert Sherwin	Chairman of Scientific Advisory Board	no data	Veri yok	Veri yok
Howard Wolpert	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Margaret Lawlor	Member of Educator Advisory Board	no data	Veri yok	Veri yok
Camille Izlar	Member of Educator Advisory Board	no data	Veri yok	Veri yok
Mary Halvorson	Member of Educator Advisory Board	no data	Veri yok	Veri yok
Steven Edelman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Anne Daly	Member of Educator Advisory Board	no data	Veri yok	Veri yok
John Buse	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Timothy Stonesifer	Independent Director	less than a year	Veri yok	Veri yok

4.0yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GOV 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).

Insulet Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Independent Chairman recently sold €1.0m worth of stock

Independent Chairman recently sold €1.2m worth of stock

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Announces Board Changes

Director & Advisor recently sold €2.3m worth of stock

Recent updates

Now 25% overvalued after recent price rise

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Omnipod 5 App for Iphone Now Fully Available in the United States

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Independent Chairman recently sold €1.0m worth of stock

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Second quarter 2024 earnings released: EPS: US$2.69 (vs US$0.39 in 2Q 2023)

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold €1.2m worth of stock

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.74 (vs US$0.34 in 1Q 2023)

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Investor sentiment deteriorates as stock falls 17%

Full year 2023 earnings released: EPS: US$2.96 (vs US$0.066 in FY 2022)

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Now 20% undervalued

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Director & Advisor recently sold €2.3m worth of stock

Now 21% undervalued after recent price drop

Insulet Corporation Provides Revenue Guidance for the Fourth Quarter and Year Ending December 31, 2023

Third quarter 2023 earnings released: EPS: US$0.74 (vs US$0.075 loss in 3Q 2022)

Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone

New minor risk - Share price stability

Insulet Corporation Announces CFO Transition

Insulet Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Insulet Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System in Germany

Second quarter 2023 earnings released: EPS: US$0.39 (vs US$0.51 loss in 2Q 2022)

Insulet Corporation to Report Q2, 2023 Results on Aug 08, 2023

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery System Is Now Available in the United Kingdom

Insider recently bought €933k worth of stock

Bret Christensen, Executive Vice President, Chief Commercial Officer Will Be Leaving Insulet Corporation

First quarter 2023 earnings released: EPS: US$0.34 (vs US$0.40 in 1Q 2022)

Executive VP recently sold €367k worth of stock

Full year 2022 earnings released: EPS: US$0.066 (vs US$0.25 in FY 2021)

Insulet Corporation (NasdaqGS:PODD) acquired Assets of Automated Glucose Control LLC for $25 million.

Insulet Corporation to Report Q4, 2022 Results on Feb 23, 2023

Insulet Corporation Announces Executive Changes

Executive VP & Chief Commercial Officer recently sold €854k worth of stock

Insulet Corporation Announces Medical Device Correction for the Omnipod 5 Automated Insulin Delivery System

Third quarter 2022 earnings released: US$0.075 loss per share (vs US$0.18 profit in 3Q 2021)

Insulet Corporation Issued Voluntary Medical Device Correction for Omnipod DASH® Personal Diabetes Manager on October 17, 2022

Insulet Corporation Provides Revenue Guidance for the Quarter Ending December 31, 2022

Insulet Corporation to Report Q3, 2022 Results on Nov 03, 2022

Executive VP & Chief Commercial Officer recently sold €768k worth of stock

Insulet Corporation Announces FDA Clearance of Omnipod® 5 for Children Aged Two Years and Older with Type 1 Diabetes

Second quarter 2022 earnings released: US$0.51 loss per share (vs US$0.38 loss in 2Q 2021)

Insulet Corporation Provides Revenue Guidance for the Quarter Ending September 30, 2022 and Year Ending December 31, 2022

Insulet Corporation Announces Full Market Release of Omnipod 5 Automated Insulin Delivery System

Insulet Corporation to Report Q2, 2022 Results on Aug 04, 2022

Executive VP & COO recently sold €1.2m worth of stock

Omnipod(R) 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years

Dexcom Says Not in Active Merger Talks

Dexcom Reportedly in Talks to Acquire Insulet

First quarter 2022 earnings released

Insulet Corporation Provides Revenue Guidance for the Quarter Ending June 30, 2022 and Full Year Ending December 31, 2022

Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes

Insulet Corporation, Annual General Meeting, May 24, 2022

Insulet Corporation to Report Q1, 2022 Results on May 05, 2022

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2022 and Year Ending December 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations